Hangzhou Bailing (Biolynx) Biotechnology Co., Ltd. is a national level high-tech enterprise focused on the research and development, production and sale of high-quality pathology IHC antibodies.

Biolynx’s new generation antibody development platform-R2mAb® utilizes innovative proprietary antibody engineering technology to develop and produce recombinant rabbit monoclonal antibodies in mammalian cells. Monoclonal antibodies produced on the platform are further engineered and optimized for superior performance according to the intended uses. 

Biolynx provides high quality recombinant rabbit monoclonal antibodies as either raw material for IHC antibody manufacturers or finished products for pathology IHC application.